The cord blood industry came into existence in the early 1990’s with the formation of several cord blood banks in the U.S. and worldwide. It has also been almost 40 years since it was first proposed that stem and progenitor cells were present in human cord blood. [Read more…]
Cord Blood
Because cord blood present within a newborn’s umbilical is rich with stem cells, it can be collected and stored for future medical use.
Cord Blood and Tissue Banking Competitors Consolidate in All Major Markets
Cord blood and tissue banking is the collection and preservation of the valuable cells within the umbilical cord of a newborn for future medical use. For both therapeutic and financial reasons, the cord blood industry has been witnessing record levels of M&A activity in recent years. Today, more than 70% of the global cord blood market is controlled by the world’s 12 largest cord blood banking operators. [Read more…]
Cord Blood Industry Consolidation Escalates in 2022
The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.
Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.
Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]
StemCyte Reports Successful Phase I Trial Using Cord Blood to Treat Cerebral Stroke
StemCyte Announces Successful Outcome in Phase I Clinical Trial for Treating Acute Cerebral Stroke Using Allogeneic Human Umbilical Cord Blood
StemCyte is a portfolio company of Microbio Group focusing on new drug discovery in cell therapy with operations in the U.S., Taiwan, and India
BALDWIN PARK, Calif., Jan. 26, 2022 — Southern California cord blood therapeutics company StemCyte Inc. is announcing successful preliminary results for Phase I of the company’s clinical trial for treating acute cerebral stroke using monocytes from allogeneic human umbilical cord blood (hUCB). [Read more…]
ReeLabs: Cord Blood Banking in India (Population 1.4 Billion)
ReeLabs is a leading cord blood bank in India. Cord blood banking in this region is of historic importance, because India has an astounding population of 1.4 billion. Representing 18% of the global population, nearly one-in-five people lives in India, placing it head-to-head with China as the world’s most populous country. India’s population growth is fueled by a birth rate (19 births/1,000 population) that substantially exceeds its death rate (7.3 deaths/1,000 population).
If you’re involved with cord blood banking, then you need to pay attention to this enormous and rapidly growing consumer market. In this interview with Dr. Abhijit Bopardikar, Director of ReeLabs, he explains the rise of cord blood banking within India and discusses the importance of pairing stem cell therapy and research applications with stem cell storage services.
